bosulif
pfizer europe ma eeig - bosutinib (sous forme de monohydrate) - leucémie, myéloïde - antineoplastic agents, protein kinase inhibitors - bosulif est indiqué pour le traitement de patients adultes atteints:nouvellement diagnostiqué en phase chronique (cp) à chromosome philadelphie positif de leucémie myéloïde chronique (lmc ph+). cp, la phase accélérée (pa), et le souffle de la phase (bp) de la lmc ph+ préalablement traités avec un ou plusieurs inhibiteur de la tyrosine kinase(s) [tki(s)] et pour qui l'imatinib, le nilotinib et le dasatinib ne sont pas considérés comme les options de traitement appropriées.
blincyto
amgen europe b.v. - blinatumomab - cellule précurseur leucémie lymphoblastique - lymphome - agents antinéoplasiques - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
valaciclovir ab 250 mg compr. pellic.
aurobindo sa-nv - chlorhydrate de valaciclovir 305,85 mg - eq. valaciclovir 250 mg - comprimé pelliculé - 250 mg - chlorhydrate de valaciclovir 305.85 mg - valaciclovir
valaciclovir ab 1 000 mg compr. pellic.
aurobindo sa-nv - chlorhydrate de valaciclovir 1223,4 mg - eq. valaciclovir 1000 mg - comprimé pelliculé - 1000 mg - chlorhydrate de valaciclovir 1223.4 mg - valaciclovir
valaciclovir ab 500 mg compr. pellic.
aurobindo sa-nv - chlorhydrate de valaciclovir 611,7 mg - eq. valaciclovir 500 mg - comprimé pelliculé - 500 mg - chlorhydrate de valaciclovir 611.7 mg - valaciclovir
valaciclovir ab 1 000 mg compr. pellic.
aurobindo sa-nv - chlorhydrate de valaciclovir 1223,4 mg - eq. valaciclovir 1000 mg - comprimé pelliculé - valaciclovir
valaciclovir ab 250 mg compr. pellic.
aurobindo sa-nv - chlorhydrate de valaciclovir 305,85 mg - eq. valaciclovir 250 mg - comprimé pelliculé - valaciclovir
valaciclovir ab 500 mg compr. pellic.
aurobindo sa-nv - chlorhydrate de valaciclovir 611,7 mg - eq. valaciclovir 500 mg - comprimé pelliculé - valaciclovir
doxycycline marie-jose plotkine 50 mg, comprimé pelliculé
marie josé plotkine - doxycycline base - comprimé - 50 mg - composition pour un comprimé > doxycycline base : 50 mg . sous forme de : hyclate de doxyxycline 51,71 mg